Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc., as indicated in the metadata) on February 10, 2019. The filing discloses executive compensation decisions approved by the Board of Directors, specifically regarding 2018 performance bonuses, 2019 base salary adjustments, and new equity grants for Named Executive Officers (NEOs).
Key Financial Metrics and Compensation Details
The filing does not report operational financial metrics such as revenue, profit, cash flow, or debt. Instead, it details specific compensation figures approved for the NEOs:
| Named Executive Officer | 2018 Bonus Payment | 2019 Base Salary | Stock Options Granted | RSUs Granted |
|---|---|---|---|---|
| Vincent J. Angotti (CEO) | $330,000 | $618,000 | 400,000 | 200,000 |
| Pamela P. Palmer (CMO) | $190,842 | $481,800 | 137,500 | 68,750 |
| Raffi Asadorian (CFO) | $160,000 | $430,000 | 137,500 | 68,750 |
| Badri Dasu (Chief Engineering Officer) | $119,534 | $351,800 | 100,000 | 50,000 |
| Lawrence G. Hamel (Chief Development Officer) | $119,534 | $351,800 | 100,000 | 50,000 |
Equity Vesting Terms:
- Stock Options: Vesting commenced February 11, 2019. 25% vests on the one-year anniversary, with the remainder vesting monthly over the subsequent 36 months.
- RSUs: Vesting commenced February 11, 2019. 33.3% vests annually over three years.
Material Changes
The filing reports the following material changes effective retroactively to January 1, 2019, or as of February 10, 2019:
- Approval of 2018 cash bonuses under the established Cash Bonus Plan.
- Adjustment of 2019 base salaries for all listed NEOs.
- Grant of new stock options and restricted stock units under the 2011 Equity Incentive Plan.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency noted is that all equity awards are subject to the recipient's "Continuous Service" as defined in the Company's Equity Incentive Plan; vesting ceases upon termination of service.
Investor Verification Checklist
- Verify the correct registrant name is AcelRx Pharmaceuticals, Inc., not TalpherA, Inc.
- Confirm the total cash compensation impact ($1,000,000+ in bonuses and salary adjustments) relative to the company's cash position in the most recent 10-K.
- Review the 2011 Equity Incentive Plan (referenced in the 2017 10-K) to understand dilution implications of the 1,000,000 total new equity units granted.
- Check for any subsequent filings regarding the actual payment of the 2018 bonuses or changes in executive tenure.